Elizabeth A. Stephenson

A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population.

Both slowed and regularized ventricular rate provide hemodynamic benefits to patients with atrial fibrillation and thus constitute a primary therapeutic goal. The return to sinus rhythm obviously reaches this goal and has been the preferred strategy over several decades. Given that recurrence of atrial fibrillation is frequent in the face of both pharmacological and ablation-based invasive therapy, and that side effects may limit their use, rhythm control approaches may frequently fall short of expected clinical benefits. In that situation, rate control becomes the alternate strategy. In fact, a number of recent clinical trials comparing rhythm and rate control strategies consistently reported net benefits of rate control therapy (see1,2 for review). Accordingly, for many patients rate control is becoming the preferred strategy while rhythm control is being targeted when needed and/or possible.1 Rate control is primarily achieved by drug-induced conduction impairment of the AV node. When this approach fails, ablation-induced third-degree AV block coupled with ventricular pacing may be considered.3,4 Several other approaches are currently under scrutiny: ventricular pacing without AV block, slow pathway ablation, gene therapy, and selective ganglionic parasympathetic stimulation.3 The modulation of AV nodal function by cardiac ganglionic stimulation may prove to be of significant value in heart failure patients in whom antiarrhythmic drug-induced depression of ventricular function must be avoided.5-8 An added benefit is that a normal ventricular activation sequence is maintained. Selective ganglionic stimulation combined with ventricular pacing may provide further benefits by achieving a slowed and regularized ventricular rate in spite of persistent atrial fibrillation.9 The Soos et al. study in the current issue10 raises the possibility that ganglionic stimulation may be feasible with currently available pacemaker technology. The concept of rate control through parasympathetic stimulation is derived from pioneering experimental work showing that selective AV node conduction slowing can be achieved through local cardiac nerve stimulation.11-15 Effective parasympathetic ventricular rate slowing during atrial fibrillation has been reached in animals with nerve stimulation applied endocardially in the vicinity of AV node,16 transvenous catheter stimulation from the coronary sinus,5 and local electrical stimulation of inferior interatrial parasympathetic ganglionated plexus.7-10 In humans, transvenous

Arrhythmias in a contemporary fontan cohort: prevalence and clinical associations in a multicenter cross-sectional study.

OBJECTIVES Our aim was to examine the prevalence of arrhythmias and identify independent associations of time to arrhythmia development. BACKGROUND Since introduction of the Fontan operation in 1971, long-term results have steadily improved with newer modifications. However, atrial arrhythmias are frequent and contribute to ongoing morbidity and mortality. Data are lacking regarding the prevalence of arrhythmias and risk factors for their development in the current era. METHODS The Pediatric Heart Network Fontan Cross-Sectional study evaluated data from 7 centers, with 520 patients age 6 to 18 years (mean 8.6 +/- 3.4 years after the Fontan operation), including echocardiograms, electrocardiograms, exercise testing, parent-reported Child Health Questionnaire (CHQ) results, and medical history. RESULTS Supraventricular tachycardias were present in 9.4% of patients. Intra-atrial re-entrant tachycardia (IART) was present in 7.3% (32 of 520). The hazard of IART decreased until 4 to 6 years post-Fontan, and then increased with age thereafter. Cardiac anatomy and resting heart rate (including marked bradycardia) were not associated with IART. We identified 3 independent associations of time to occurrence of IART: lower CHQ physical summary score (p < 0.001); predominant rhythm (p = 0.002; highest risk with paced rhythm), and type of Fontan operation (p = 0.037; highest risk with atriopulmonary connection). Time to IART did not differ between patients with lateral tunnel and extracardiac conduit types of Fontan repair. Ventricular tachycardia was noted in 3.5% of patients. CONCLUSIONS Overall prevalence of IART was lower in this cohort (7.3%) than previously reported. Lower functional status, an atriopulmonary connection, and paced rhythm were determined to be independently associated with development of IART after Fontan. (Relationship Between Functional Health Status and Ventricular Performance After Fontan-Pediatric Heart Network; NCT00132782).

Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease.

Patients with congenital heart disease are vulnerable to atrial tachyarrhythmias, especially after atrial surgeries. We evaluated the efficacy of atrial arrhythmia detection and antitachycardia pacing (ATP) using the Medtronic AT500 pacemaker in 28 patients with congenital heart disease (age 30 +/- 18 years). Of 15 patients with atrial arrhythmias, 14 had atrial tachycardia events that were appropriately detected. ATP was enabled for 167 treatable episodes, successfully converting 90 (54%). Rhythms classified as ventricular tachycardia were detected 127 times, yet most were actually atrial or sinus tachycardia with 1:1 atrioventricular conduction. Atrial tachycardias in congenital heart disease are amenable to ATP algorithms in the AT500 pacemaker.

Complications Associated With Revision of Sprint Fidelis Leads Report From the Canadian Heart Rhythm Society Device Advisory Committee

Background— It has been observed that replacement of an implantable cardioverter-defibrillator generator in response to a device advisory may be associated with a substantial rate of complications, including death. The risk of lead revision in response to a lead advisory has not been determined previously. Methods and Results— Twenty-five implantable cardioverter-defibrillator implantation and follow-up centers from the Canadian Heart Rhythm Society Device Advisory Committee were surveyed to assess complication rates as a result of lead revisions due to the Sprint Fidelis advisory issued in October 2007. As of June 1, 2009, there had been 310 lead failures found in 6237 Sprint Fidelis leads in Canada (4.97%) over a follow-up of 40 months. There were 469 leads to be revised, 66% for confirmed fracture. Of the patients who underwent revision, 95% had a new lead inserted, whereas 4% had a pace/sense lead added. The lead was removed in 248 cases (53%), by simple traction in 61% and by laser lead extraction in 33%. Complications were encountered in 14.5% of the lead revisions; 7.25% of these were major, whereas 7.25% were minor. There were 2 deaths (0.43%). The overall risk of complications (19.8%) was greater in those who underwent lead removal at the time of revision than in those whose leads were abandoned (8.6%; P=0.0008). Conclusions— The overall rate of major complications that arose from lead revision due to the Sprint Fidelis advisory was significant. This must be taken into account when lead revision is planned in those patients who have not yet demonstrated an abnormality in lead performance.

Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee

BACKGROUND The Medtronic Sprint Fidelis family of leads has recently been the subject of a widespread advisory. Lead failure rates are estimated at 2.3% at 30 months, 2.6 times the failure rate of the reference Medtronic 6947 lead. OBJECTIVE The purpose of this study was to contact pediatric and adult implantable cardioverter-defibrillator (ICD) implant centers across Canada to determine the short-term response to the October 15, 2007 Medtronic Fidelis lead advisory. METHODS All centers completed an 11-part survey to assess the frequency and presentation of lead failure, operator characteristics, and centers response. RESULTS Lead failure was noted in 80 (1.29%) of 6,181 patients at 21.0 months, with inappropriate shocks experienced in 45 (56%) of the 80 patients (overall risk 0.73%). No deaths were attributed to lead failure. Sensing was the primary form of failure, seen in 60 leads (75%), with pacing failure in 10 (13%), and high-voltage failure in 15 (19%). Assessment of the previous routine ICD interrogation prior to the advisory or lead failure demonstrated evidence of altered lead performance in only 8 (10%) of the 80 leads. Inappropriate shocks typically were multiple (median 7, range 1-122), with a single shock seen in only 5 patients. Lead failure was noted in 18 of 23 centers, representing 89.8% of leads implanted, with at least one failure noted in 15 of 16 centers that implanted more than 200 leads. Forty-seven of the 135 operators in the 23 institutions implanted the 80 leads that subsequently failed. Only 16 operators were involved in more than a single lead that subsequently failed; seven operators participated in three or more leads that subsequently failed. Seven centers planned to replace leads in most pacing-dependent patients, and two centers planned to replace leads in patients unable to hear the alert tone. CONCLUSION This national experience suggests a Fidelis lead failure rate of 1.29% at 21 months, most often presenting with multiple inappropriate shocks without evidence of impending failure from routine lead follow-up. Lead failure did not appear to cluster around specific operators or around high-volume or low-volume implant centers.

Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age

OBJECTIVES Our objective was to determine the relationship between functional outcome and abnormalities of heart rate and rhythm after the Fontan operation. METHODS The National Heart, Lung, and Blood Institute Pediatric Heart Network conducted a cross-sectional analysis of patients who had undergone a Fontan procedure at the 7 network centers. Analysis was based on 521 patients with an electrocardiogram (n = 509) and/or bicycle exercise test (n = 404). The Child Health Questionnaire parent report and the oxygen consumption at the anaerobic threshold were used as markers of functional outcome. RESULTS Various Fontan procedures had been performed: intracardiac lateral tunnel (59%), atriopulmonary connection (14%), extracardiac later tunnel (13%), and extracardiac conduit (11%). Prior volume unloading surgery was performed in 389 patients: bidirectional Glenn (70%) and hemi-Fontan (26%). A history of atrial tachycardia was noted in 9.6% of patients and 13.1% of patients had a pacemaker. Lower resting heart rate and higher peak heart rate were each weakly associated with better functional status, as defined by higher anaerobic threshold (R = -0.18, P = .004, and R = 0.16, P = .007, respectively) and higher Child Health scores for physical functioning (R = -0.18, P < .001, and R = 0.17, P = .002, respectively). Higher anaerobic threshold was also independently associated with younger age and an abnormal P-axis. Resting bradycardia was not associated with anaerobic threshold or Child Health scores. CONCLUSIONS In pediatric patients (6-18 years) after the Fontan procedure, a lower resting heart rate and a higher peak heart rate are each independently associated with better physical function as measured by anaerobic threshold and Child Health scores. However, these correlations are weak, suggesting that other, nonrhythm and nonrate, factors may have a greater impact on the functional outcome of pediatric patients after the Fontan operation.

The Study of Antiarrhythmic Medications in Infancy (SAMIS) A Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Digoxin Versus Propranolol for Prophylaxis of Supraventricular Tachycardia in Infants

Background—Supraventricular tachycardia (SVT) is one of the most common conditions requiring emergent cardiac care in children, yet its management has never been subjected to a randomized controlled clinical trial. The purpose of this study was to compare the efficacy and safety of the 2 most commonly used medications for antiarrhythmic prophylaxis of SVT in infants: digoxin and propranolol. Methods and Results—This was a randomized, double-blind, multicenter study of infants <4 months with SVT (atrioventricular reciprocating tachycardia or atrioventricular nodal reentrant tachycardia), excluding Wolff-Parkinson-White, comparing digoxin with propranolol. The primary end point was recurrence of SVT requiring medical intervention. Time to recurrence and adverse events were secondary outcomes. Sixty-one patients completed the study, 27 randomized to digoxin and 34 to propranolol. SVT recurred in 19% of patients on digoxin and 31% of patients on propranolol (P=0.25). No first recurrence occurred after 110 days of treatment. The 6-month recurrence-free status was 79% for patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrences in either group between 6 and 12 months. There were no deaths and no serious adverse events related to study medication. Conclusions—There was no difference in SVT recurrence in infants treated with digoxin versus propranolol. The current standard practice may be treating infants longer than required and indicates the need for a placebo-controlled trial. Clinical Trial Registration Information—http://clinicaltrials.gov; NCT-00390546.

Electrophysiological interventions for inherited arrhythmia syndromes.

IInherited arrhythmia syndromes are electrical myopathies with genetic origins and risk of sudden death. They may present from infancy through adulthood, although the specific diseases have stereotypic but variable phenotypic onset and severity. There is clinical and genetic overlap among the syndromes, with variable penetrance and expressivity. Although underlying mechanisms of arrhythmogenesis may differ between syndromes, the electrophysiological (EP), pharmacological, and interventional options overlap. Specifics of the genetics, pharmacological therapies, and lifestyle modifications have been reviewed recently and are beyond the scope of this article, which focuses on interventional electrophysiology for inherited arrhythmias. The congenital long-QT syndromes (LQTSs) are the prototypic group of inherited arrhythmias. They were initially described as autosomal-recessive LQTSs with congenital sensorineural hearing loss, Jervell and Lange-Nielson (JLN) syndrome,1 and the more common autosomal-dominant LQTS with normal hearing, Romano-Ward syndrome.2,3 LQTS is caused by mutations in ion channel (or related anchoring protein) –encoding genes,4–6 presenting with prolonged QTc, stress-induced syncope, ventricular arrhythmias, or sudden cardiac death (SCD). The diagnosis is ascertained from clinical symptom complex, family history, ECG manifestations (at baseline or with provocative stimulation), and genetic testing. The principal treatment is pharmacological for most LQTS patients.7,8 ### Interventions for Congenital Long-QT Syndromes #### Catheter Ablation There is little role for diagnostic EP testing in LQTS. Studies have shown that programmed ventricular stimulation, QT interval response to pacing, and infusion of β-blocking medication in LQTS are of limited value.9 Monophasic action potential studies demonstrated afterdepolarizations but were not prognostic, and proarrhythmia can occur with ventricular stimulation.10 #### Left Cardiac Sympathetic Denervation Left cardiac sympathetic denervation (LCSD) can reduce cardiac events in LQTS but is not commonly performed at many institutions.11 Indications for LCSD include failure of medical therapy or frequent implantable cardioverter-defibrillator (ICD) shocks. Clinical results vary, likely because of the level of sympathetic denervation and operator experience. Left cervicothoracic sympathectomy involves resection of …

Predictors of myocardial recovery in pediatric tachycardia-induced cardiomyopathy

BACKGROUND Tachycardia-induced cardiomyopathy (TIC) carries significant risk of morbidity and mortality, although full recovery is possible. Little is known about the myocardial recovery pattern. OBJECTIVE The purpose of this study was to determine the time course and predictors of myocardial recovery in pediatric TIC. METHODS An international multicenter study of pediatric TIC was conducted. Children ≤18 years with incessant tachyarrhythmia, cardiac dysfunction (left ventricular ejection fraction [LVEF] <50%), and left ventricular (LV) dilation (left ventricular end-diastolic dimension [LVEDD] z-score ≥2) were included. Children with congenital heart disease or suspected primary cardiomyopathy were excluded. Primary end-points were time to LV systolic functional recovery (LVEF ≥55%) and normal LV size (LVEDD z-score <2). RESULTS Eighty-one children from 17 centers met inclusion criteria: median age 4.0 years (range 0.0-17.5 years) and baseline LVEF 28% (interquartile range 19-39). The most common arrhythmias were ectopic atrial tachycardia (59%), permanent junctional reciprocating tachycardia (23%), and ventricular tachycardia (7%). Thirteen required extracorporeal membrane oxygenation (n = 11) or ventricular assist device (n = 2) support. Median time to recovery was 51 days for LVEF and 71 days for LVEDD. Two (4%) underwent heart transplantation, and 1 died (1%). Multivariate predictors of LV systolic functional recovery were age (hazard ratio [HR] 0.61, P = .040), standardized tachycardia rate (HR 1.16, P = .015), mechanical circulatory support (HR 2.61, P = .044), and LVEF (HR 1.33 per 10% increase, p=0.005). For normalization of LV size, only baseline LVEDD (HR 0.86, P = .008) was predictive. CONCLUSION Pediatric TIC resolves in a predictable fashion. Factors associated with faster recovery include younger age, higher presenting heart rate, use of mechanical circulatory support, and higher LVEF, whereas only smaller baseline LV size predicts reverse remodeling. This knowledge may be useful for clinical evaluation and follow-up of affected children.

PACES/HRS Expert Consensus Statement on the Evaluation and Management of Ventricular Arrhythmias in the Child With a Structurally Normal Heart

and Management of Ventricular Arrhythmias in the Child With a Structurally Normal Heart Jane E. Crosson, MD, FACC (Chair), David J. Callans, MD, FHRS, FACC, FAHA (Chair), David J. Bradley, MD, FACC, FAAP, Anne Dubin, MD, FHRS, FAHA, FACC, Michael Epstein, MD, FACC, CCDC, Susan Etheridge, MD, FHRS, FACC, FAAP, CEPS, Andrew Papez, MD, FHRS, CCDS, John R. Phillips, MD, FAAP, FHRS, FACC, Larry A. Rhodes, MD, FAAP, FHRS, FACC, Philip Saul, MD, FHRS, FACC, FAHA, Elizabeth Stephenson, MD, MSc, FHRS, CCDS, CEPS, William Stevenson, MD, FAHA, FHRS, FACC, Frank Zimmerman, MD, FAHA, FHRS From the Bloomberg Children’s Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, C.S. Mott Children’s Hospital, Anne Arbor, Michigan, Lucile Packard Children’s Hospital, Stanford School of Medicine, Stanford, California, Maine Medical Center, Portland, Maine, University of Utah and Primary Children’s Medical Center, Salt Lake City, Utah, Phoenix Children’s Hospital/Arizona Pediatric Cardiology Consultants Phoenix, Arizona, WVUH Children’s Hospital, Morgantown, West Virginia, Nationwide Children’s Hospital, Ohio State University, Columbus, Ohio, University of Toronto, Toronto, Ontario, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, and Advocate Heart Institute for Children Advocate Children’s Hospital, Oak Lawn, Illinois.